Browsing by Author "Caner B."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Scintigraphic evaluation of synovial inflammation in rheumatoid arthritis with 99mtechnetium-labelled human polyclonal immunoglobulin G
    (2001) Cindaş A.; Gökçe-Kutsal Y.; Kirth P.O.; Caner B.
    The aim of this study was to investigate whether 99mtechnetium-labelled polyclonal human immunoglobulin G (99mTc-IgG) scintigraphy reflects synovial inflammation in patients with rheumatoid arthritis (RA). We evaluated 29 patients with RA for this reason and found a highly significant correlation between total scintigraphic scores and total tenderness scores (r = 0.781, P < 0.001). A significant correlation was also found between 99mTc-IgG scintigraphic scores and tenderness in all joints other than the shoulders. The 99mTc-IgG scintigraphy had a sensitivity of 69% and specificity of 88% in cases with tenderness and 72% and 81%, respectively, in cases with swelling. Total scintigraphic scores were correlated with serum levels of C-reactive protein (r = 0.401, P < 0.05) but not with erythrocyte sedimentation rate (r = 0.149, P > 0.05). The correlation between disease activity scores and total scintigraphic scores was also found to be significant (r = 0.812, P < 0.001). We suggest that 99mTc-IgG scintigraphy is a reliable and objective method in detecting synovial activity and can be appropriate for observing disease prognosis in clinical trials with RA.
  • No Thumbnail Available
    Item
    Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
    (Springer, 2024) Beypınar İ.; Demir H.; Yaslıkaya Ş.; Köşeci T.; Demir B.; Çolak G.; Ağaoğlu A.B.; Şahbazlar M.; Şancı P.C.; Çabuk D.; Işık U.; Şahin E.; Coşkun A.; Caner B.; Aykut T.; Artaç M.; Duygulu M.E.; Sever N.; Öksüz S.; Turan N.; Aykan M.B.; Tüzün E.K.; Uysal M.; Uğurlu İ.; Sakin A.; Acar C.; Özaşkın D.; Şakalar T.; Keskinkılıç M.; Yavuzşen T.; Köse N.; Ertürk İ.; Yıldırım N.; Balçık O.Y.; Alkan A.; Selvi O.; Erçin E.; Ünal O.Ü.; Karaçin C.
    Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.